Nexalin Technology shares drop 59.99% premarket amid significant financial challenges despite clinical advancements.

Nexalin Technology fell 59.99% in premarket trading amid concerns over its deteriorating financial health, despite recent clinical progress in neurostimulation technology. The company highlighted peer-reviewed validation of its DIFS™ system for mental health conditions and submitted clinical data to the FDA under its "mood-military-memory" strategy. However, financial disclosures revealed a -14.7% three-year revenue decline, a -5527.39% net margin, and an Altman Z-Score of -11.72 signaling bankruptcy risk. These metrics, coupled with a Piotroski F-Score of 2 and high volatility (beta of 2.72), overshadowed clinical advancements, triggering a sharp selloff as investors reacted to unsustainable operational performance and liquidity challenges.